Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Liabilities and Shareholders Equity: 2018-2024

Historic Liabilities and Shareholders Equity for Whitehawk Therapeutics (WHWK) over the last 7 years, with Dec 2024 value amounting to $70.3 million.

  • Whitehawk Therapeutics' Liabilities and Shareholders Equity rose 94.89% to $167.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $652.2 million, marking a year-over-year increase of 51.38%. This contributed to the annual value of $70.3 million for FY2024, which is 46.90% down from last year.
  • As of FY2024, Whitehawk Therapeutics' Liabilities and Shareholders Equity stood at $70.3 million, which was down 46.90% from $132.4 million recorded in FY2023.
  • Over the past 5 years, Whitehawk Therapeutics' Liabilities and Shareholders Equity peaked at $184.2 million during FY2022, and registered a low of $18.8 million during FY2020.
  • Over the past 3 years, Whitehawk Therapeutics' median Liabilities and Shareholders Equity value was $132.4 million (recorded in 2023), while the average stood at $129.0 million.
  • As far as peak fluctuations go, Whitehawk Therapeutics' Liabilities and Shareholders Equity slumped by 52.86% in 2020, and later spiked by 738.83% in 2021.
  • Whitehawk Therapeutics' Liabilities and Shareholders Equity (Yearly) stood at $18.8 million in 2020, then surged by 738.83% to $157.9 million in 2021, then increased by 16.67% to $184.2 million in 2022, then declined by 28.12% to $132.4 million in 2023, then plummeted by 46.90% to $70.3 million in 2024.